MRVI

Maravai Lifesciences Holdings Inc

MRVI, USA

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

https://www.maravai.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MRVI
stock
MRVI

MRVI: Wells Fargo Maintains Rating and Raises Price Target | MRV GuruFocus

Read more →
MRVI
stock
MRVI

Maravai LifeSciences Holdings, Inc. $MRVI Stock Holdings Boosted by Immersion Corp MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$3.8571

Analyst Picks

Strong Buy

5

Buy

1

Hold

7

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Medium

2.12

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-10.41 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-3.01 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-43.42 %

Low 5%

High 15%

Debt to Equity

-

Very Low

1.70

Low 1

High 0.3

Investors

* Institutions hold a combined 91.59% of the total shares of Maravai Lifesciences Holdings Inc

1.

GTCR LLC

(13.9275%)

since

2025/06/30

2.

12 West Capital Management LP

(8.6546%)

since

2025/06/30

3.

BlackRock Inc

(6.7005%)

since

2025/06/30

4.

Vanguard Group Inc

(6.4838%)

since

2025/06/30

5.

BRAIDWELL LP

(5.7737%)

since

2025/06/30

6.

Mackenzie Investments

(4.195%)

since

2025/06/30

7.

Canada Life US Small-Mid Cap Growth F

(3.1611%)

since

2025/06/30

8.

Renaissance Technologies Corp

(2.8935%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(2.7196%)

since

2025/07/31

10.

Mirabella Financial Services LLP

(2.592%)

since

2025/06/30

11.

Point72 (DIFC) Ltd

(2.5709%)

since

2025/06/30

12.

UBS Group AG

(2.2341%)

since

2025/06/30

13.

iShares Russell 2000 ETF

(2.075%)

since

2025/08/31

14.

Geode Capital Management, LLC

(2.0625%)

since

2025/06/30

15.

Morgan Stanley - Brokerage Accounts

(1.9886%)

since

2025/06/30

16.

T. Rowe Price Investment Management,Inc.

(1.8273%)

since

2025/06/30

17.

Philosophy Capital Management LLC

(1.7924%)

since

2025/06/30

18.

State Street Corp

(1.6459%)

since

2025/06/30

19.

Two Sigma Advisers, LLC

(1.5376%)

since

2025/06/30

20.

T. Rowe Price Small-Cap Stock

(1.3515%)

since

2025/07/31

21.

Tejara Capital Ltd

(1.3419%)

since

2025/06/30

22.

Deutsche Bank AG

(1.2955%)

since

2025/06/30

23.

Systematic Financial Management LP

(1.1555%)

since

2025/06/30

24.

CenterBook Partners LP

(1.1298%)

since

2025/06/30

25.

Vanguard Small Cap Index

(0.9658%)

since

2025/07/31

26.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9032%)

since

2025/07/31

27.

Fidelity Small Cap Index

(0.8475%)

since

2025/06/30

28.

Columbia Small Cap Value Discv A

(0.7933%)

since

2025/07/31

29.

Columbia Small Cap Value Discovery Fund

(0.7715%)

since

2025/06/30

30.

T. Rowe Price Small-Cap Value

(0.7601%)

since

2025/07/31

31.

Xtrackers MSCI World Swap ETF 1C

(0.7488%)

since

2025/07/31

32.

iShares Russell 2000 Value ETF

(0.7317%)

since

2025/08/31

33.

T. Rowe Price Instl Small-Cap Stock

(0.6826%)

since

2025/07/31

34.

Vanguard Small Cap Growth Index Inv

(0.5423%)

since

2025/07/31

35.

Xtrackers S&P 500 Swap ETF 1C

(0.5115%)

since

2025/07/31

36.

Royce Micro Cap Trust

(0.4872%)

since

2025/06/30

37.

Fidelity Extended Market Index

(0.4568%)

since

2025/07/31

38.

iShares Biotechnology ETF

(0.437%)

since

2025/08/31

39.

Pender Global Small/Mid Cap Eq F

(0.4247%)

since

2025/05/31

40.

IG Mackenzie U.S. Small-Mid Cap Growth C

(0.4195%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.066

Latest Release

Date

2025-09-30

EPS Actual

-0.08

EPS Estimate

-0.0784

EPS Difference

-0.0016

Surprise Percent

-2.0408%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.